MetaVia Inc. is trading 13.2% down at $2.23 in pre-market action as investors digest detailed data from the company's American Diabetes Association (ADA) 2026 presentations.
- The stock is pulling back sharply from its recent $2.57 close, following a volatile run where shares had previously spiked as much as 45.9%.
- The downward move comes as traders unwind momentum after the acceptance of three late-breaking abstracts for obesity and cardiometabolic candidates DA-1726 and vanoglipel.